Diuretics. Clinical pharmacology and therapeutic use (Part I).
25 years have elapsed since the introduction of the first effective oral diuretic, chlorothiazide. Diuretics are now amongst the most widely prescribed drugs in clinical practice worldwide. Availability of these drugs has not only brought therapeutic benefit to countless numbers of patients but it has at the same time provided valuable research tools with which to investigate the functional behaviour of the kidney and other electrolyte-transporting tissues. Despite many remaining gaps in our knowledge of the biochemical processes involved in diuretic drug action, available compounds can be divided into 5 groups on the basis of their preferential effects on different segments of the nephron involved in tubular reabsorption of sodium chloride and water. Firstly, there is heterogeneous group of chemicals that share the common property of powerful, short-lived diuretic effects that are complete within 4 to 6 hours. These agents act on the thick ascending limb of Henle's loop and are known as 'high ceiling' or 'loop' diuretics. The second group are the benzothiadiazines and their many related heterocyclic variants, all of which localise their effects to the early portion of the distal tubule. The third group comprises the potassium-sparing diuretics which act exclusively on the Na+-K+/H+ exchange mechanisms in the late distal tubule and cortical collecting duct. The action of drugs in groups 2 and 3 is prolonged to between 12 and 24 hours. The fourth group consists of diuretics that are chemically related to ethacrynic acid but have the unusual property of combining within the same molecule the property of saluresis and uricosuria. These compounds have actions, to different individual extents, in the proximal tubule, thick ascending limb, and early distal tubule and are known as 'polyvalent' diuretics. Finally, there is a mixed group of weak or adjunctive diuretics which includes the vasodilator xanthines such as aminophylline, and the osmotically active compounds such as mannitol. Available evidence on the molecular mechanisms of action of diuretics in each group is reviewed. The haemodynamic, humoral and physical factors involved in control of electrolyte and fluid handling by the kidney in normal conditions and pathological states are discussed in relation to rational choices of different diuretics in the treatment of various oedematous and non-oedematous conditions.
D000818:Animals; D001581:Benzothiadiazines; D004232:Diuretics / Q000145:classification / Q000494:pharmacology* / Q000627:therapeutic use; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007678:Kidney Glomerulus / Q000187:drug effects; D007685:Kidney Tubules, Collecting / Q000187:drug effects; D007686:Kidney Tubules, Distal / Q000187:drug effects; D007687:Kidney Tubules, Proximal / Q000187:drug effects; D007700:Kinetics; D007705:Kinins / Q000502:physiology; D008138:Loop of Henle / Q000187:drug effects; D045283:Natriuretic Agents; D009399:Nephrons / Q000502:physiology; D009424:Nervous System Physiological Phenomena; D011453:Prostaglandins / Q000502:physiology; D011506:Proteins / Q000502:physiology; D012079:Renal Circulation / Q000187:drug effects; D012084:Renin-Angiotensin System / Q000187:drug effects; D049993:Sodium Chloride Symporter Inhibitors / Q000494:pharmacology; D014882:Water-Electrolyte Balance / Q000187:drug effects
D001581:Benzothiadiazines; D004232:Diuretics; D007705:Kinins; D045283:Natriuretic Agents; D011453:Prostaglandins; D011506:Proteins; D049993:Sodium Chloride Symporter Inhibitors